Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2009

View Archived Issues

Gilead enters agreement with Tibotec for fixed-dose Truvada and TMC-278

Anti-HIV activity seen with S/GSK-1349572 in preclinical and clinical studies

Gilead Sciences reports second quarter 2009 results

Anti-Abeta1-40 antibody PF-04360365 found safe and well tolerated in patients with mild AD

Sylentis receives approval to begin phase I studies with its antiglaucoma agent SYL-040012

Allergan receives FDA approval for Acuvail ophthalmic solution

Pharmaxis discloses SSAO/MAO inhibitors

Pooled data show asenapine efficacy in treating manic or mixed episodes in bipolar I disorder

Leo Pharma describes CaSR agonists for the treatment of hyperparathyroidism

Nevirapine as effective as atazanavir/ritonavir in HIV-1 patients given tenofovir DF/emtricitabine

Genecare Research Institute prepares and tests novel IKK-beta inhibitors

ARRY-872 targets Trk receptors for pain management

Affitech licenses anti-VEGF antibodies from Peregrine

Astellas and RegImmune sign agreement to develop new vaccine technology

Repros discontinues use of the Proellex 50-mg dose in clinical trials

EMEA reconfirms the safety of Lantus

FDA approves new indication for Lilly's osteoporosis drug Forteo

CHMP recommends approval for Ilaris in the treatment of CAPS

Dual Bcl-2 and microtubule antagonists claimed by Univ. Minnesota for prostate cancer therapy

Prolysis discovers novel DNA gyrase inhibitors as antibacterial agents

R-788 fails to meet efficacy endpoints in phase IIb trial in RA patients

European Commission approves Nycomed's Instanyl for breakthrough cancer pain

Cellceutix's cancer drug Kevetrin shows no significant toxicity indications in animal studies

Arno enrolls first patient in phase II AR-67 study for myelodysplastic syndrome

Promedior commences phase I PRM-151 trial in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...